Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29925695 | 0.85 | TGFBR1 (0.56) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1102440 | 0.85 | TGFBR1 (0.56) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL12663370 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL12663368 | 0.83 | TGFBR1 (0.55) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2424951 | 0.81 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL20023732 | 0.81 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL27736665 | 0.81 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1566968 | 0.79 | KDM4E (0.72) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL30989132 | 0.79 | KDM4E (0.72) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL30989133 | 0.79 | KDM4E (0.72) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025934-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-11753425-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210315876-A1 | METHODS FOR REVERSING HIV LATENCY USING BAF COMPLEX MODULATING COMPOUNDS | PURDUE RESEARCH FOUNDATION | 2021-10-14 | — | — | US | disclosed |
| US-10981876-B2 | Spiro compound and organic light emitting element comprising same | LG CHEM, LTD. | 2021-04-20 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | CYP1A2 677/4885CYP2D6 1605/4885CYP19A1 427/4885 |
| US-20240025934-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | SSB, RO60, LIFR | CYP1A2 3956/4885CYP2D6 3017/4885CYP19A1 4220/4885 |
| US-10981876-B2 | Spiro compound and organic light emitting element comprising same | RER1, RIF1, CRY1 | CYP1A2 587/4885CYP2D6 705/4885CYP19A1 119/4885 |
| US-11753425-B2 | Organic electroluminescent materials and devices | SSB, RO60, LIFR | CYP1A2 3956/4885CYP2D6 3017/4885CYP19A1 4220/4885 |
| US-20210315876-A1 | METHODS FOR REVERSING HIV LATENCY USING BAF COMPLEX MODULATING COMPOUNDS | CHD1L, SMARCC1, CHD1 | CYP1A2 4764/4885CYP2D6 4758/4885CYP19A1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.